AstraZeneca filed for FDA approval of Brilinta, a promising rival to blockbuster blood thinner Plavix. The application comes months after AstraZeneca reported that Brilinta outperformed Plavix in a late-stage study.
Published in Brief:
|Manager of Payer Relations||
Pharmacy Quality Solutions, Inc.
|Director of Product Planning Development; Market Planning, Innovation||
Blue Cross Blue Shield of Massachusetts
|Quincy , MA|
|Vice President of Medicare||
UPMC Health Plan
|National Affairs Analyst||
|Jersey City, NJ|
|Corporate Regulatory Lawyer EMEA (f/m)||
W. L. Gore & Associates GmbH
|Putzbrunn (near Munich)|